Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2015 Apr 3;14(6):1376–1384. doi: 10.1158/1535-7163.MCT-15-0036

Table 1.

L428-P L428-R Karpas-P Karpas-R
IC50 to BV 27 ± 4.8 μg/ml 236 ± 22 μg/ml 29 ± 21 ng/ml 19 ± 1.9 μg/ml
Relative resistance 1 8.7 1 655
% cells CD30+ 98% 97% 96% 59%
Median intensity CD30 280 ± 10 265 ± 5 592 ± 51 78 ± 17